Omeros Corporation
OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has compleā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$17.11
Price-0.47%
-$0.08
1Y
Price
Market Cap
$1.238b
Small
Price/Earnings 3y Avg5y Avg
7.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+580.6%
EBITDA Margin+566.7%
Net Profit Margin-146.6%
Free Cash Flow Margin+580.6%
EBITDA Margin+566.7%
Net Profit Margin-146.6%
Free Cash Flow MarginRevenue
$9.893m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
$86.170m
+2672.2%
1y CAGR+912.3%
3y CAGR+597.1%
5y CAGREPS
$1.30
+2700.0%
1y CAGR+918.2%
3y CAGR+561.5%
5y CAGRBook Value
-$63.334m
$286.173m
Assets$349.507m
Liabilities$310.632m
DebtDebt to Assets
108.6%
3.3x
Debt to EBITDAFree Cash Flow
-$94.783m
+18.4%
1y CAGR-86.7%
3y CAGR-18.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company